Benign prostatic hyperplasia as a progressive disease: A guide to the risk factors and options for medical management

International Journal of Clinical Practice

Volumn 62, Issue 7, 2008, Pages 1076-1086

  Emberton, M ^a   Cornel, E B ^b   Bassi, P F ^c   Fourcade, R O ^d   Gomez J M F ^e   Castro, R ^f  

^a INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

^b Department of Urology   (Netherlands)

^c CATHOLIC UNIVERSITY   (Italy)

^d Centre Hospitalier d'Auxerre   (France)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f GLAXOSMITHKLINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; ENZYME INHIBITOR; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; GROUPS BY AGE; HUMAN; IMPOTENCE; INTERNATIONAL PROSTATE SYMPTOM SCORE; LIBIDO; LOWER URINARY TRACT SYMPTOM; MALE SEXUAL DYSFUNCTION; MICTURITION; MONOTHERAPY; ORGAN SIZE; ORTHOSTATIC HYPOTENSION; PATIENT; PHYTOTHERAPY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC HYPERPLASIA; RISK FACTORS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 44849136157     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01785.x     Document Type: Review

References (64)

1. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol 2005 7 (Suppl. 9 S3 14.
2. Speakman MJ, Kirby RS, Joyce A et al. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 2004 93 : 985 90.
3. Boyle P, Robertson C, Mazzetta C et al. The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik Study. BJU Int 2003 92 : 409 14.
4. Madersbacher S, Alivizatos G, Nordling J et al. EAU guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004 46 : 547 54.
5. American Urological Association. Guideline on the Management of Benign Prostatic Hyperplasia (BPH). http://www.auanet.org/guidelines/bph.cfm (accessed March 2008).
6. Carballido Rodriguez J, Badia Llach X, Gimeno Collado A et al. Validity of tests for initial diagnosis and its concordance with final diagnosis in patients with suspected benign prostatic hyperplasia. Actas Urol Esp 2006 30 : 667 74.
7. Emberton M, Andriole GL, de la Rosette J et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003 61 : 267 73.
8. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 349 : 2387 98.
9. Jacobsen SJ, Girman CJ, Jacobson DJ et al. Long-term (92-month) natural history of changes in lower urinary tract symptom severity. J Urol 2000 163 (Suppl. 4 248 9.
10. Jacobsen SJ, Jacobson DJ, Girman CJ et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997 158 : 481 7.
11. Pickard R, Emberton M, Neal DE. The management of men with acute urinary retention. Br J Urol 1998 81 : 712 20.
12. Choong S, Emberton M. Acute urinary retention. BJU Int 2000 85 : 186 201.
13. Desgrandchamps F, De La Taille A, Doublet JD. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia. BJU Int 2006 97 : 727 33.
14. Flanigan RC, Reda DJ, Wasson JH et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998 160 : 12 6.
15. Kawakami J, Nickel JC. Acute urinary retention and surgery for benign prostatic hyperplasia: the patient's perspective. Can J Urol 1999 6 : 819 22.
16. Teillac P. Benign prostatic hyperplasia: patients' perception of medical treatment and their expectations. Results of a French survey involving patients treated with finasteride. Therapie 2002 57 : 473 83.
17. Emberton M, Marberger M, de la Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: the Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract 2007 62 : 18 26.
18. McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med 1998 338 : 557 63.
19. Roehrborn CG, Boyle P, Bergner D et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS study group. Urology 1999 54 : 662 9.
20. Crawford ED, Wilson SS, McConnell JD et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006 175 : 1422 6.
21. Chute CG, Panser LA, Girman CJ et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993 150 : 85 9.
22. Li M-K, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int 2005 96 : 1339 54.
23. Mochtar CA, Kiemeney LA, van Riemsdijk MM et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 2003 44 : 695 700.
24. Anderson JB, Roehrborn CG, Schalken JA et al. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 2001 39 : 390 9.
25. Roehrborn CG. Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. Urology 1998 51 (Suppl. 1 19 22.
26. Roehrborn CG, Girman CJ, Rhodes T et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology 1997 49 : 548 57.
27. Applewhite JC, Matlaga BR, McCullough DL et al. Transrectal ultrasound and biopsy in the early diagnosis of prostate cancer. Cancer Control 2001 8 : 141 50.
28. Rhodes T, Girman CJ, Jacobsen SJ et al. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 1999 161 : 1174 9.
29. Chang YL, Lin AT, Chen KK et al. Correlation between serum prostate specific antigen and prostate volume in Taiwanese men with biopsy proven benign prostatic hyperplasia. J Urol 2006 176 : 196 9.
30. Shim HB, Lee JK, Jung TY et al. Serum prostate-specific antigen as a predictor of prostate volume in Korean men with lower urinary tract symptoms. Prostate Cancer Prostatic Dis 2007 10 : 143 8.
31. Roehrborn CG, Malice M, Cook TJ et al. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001 58 : 210 6.
32. Emberton M. Definition of at-risk patients: dynamic variables. BJU Int 2006 97 (Suppl. 2 12 5.
33. Sarma AV, Jacobson DJ, McGree ME et al. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. J Urol 2005 173 : 2048 53.
34. Burnett AL, Wein AJ. Benign prostatic hyperplasia in primary care: what you need to know. J Urol 2006 175 : S19 24.
35. Lowe FC. Phytotherapy in the management of benign prostatic hyperplasia. Urology 2001 58 (Suppl. 6A 71 7.
36. Schwinn DA. The role of α1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 2001 88 (Suppl. 2 27 34.
37. MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology 2005 66 : 780 8.
38. MacDonald R, Wilt TJ, Howe RW. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU Int 2004 94 : 1263 70.
39. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia. J Urol 2003 170 : 530 47.
40. Djavan B, Chapple C, Milani S et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004 64 : 1081 8.
41. Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006 97 : 734 41.
42. Chapple CR, Wyndaele JJ, Nordling J et al. Tamsulosin, the first prostate-selective alpha 1a-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European tamsulosin study group. Eur Urol 1996 29 : 155 67.
43. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin investigator group. Urology 1998 51 : 901 6.
44. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin investigator group. Urology 1998 51 : 892 900.
45. Schulman CC, Cortvriend J, Jonas U et al. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European tamsulosin study group. Eur Urol 1999 36 : 609 20.
46. Bartsch G, Fitzpatrick JM, Schalken JA et al. Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU Int 2004 93 (Suppl. 1 27 9.
47. Clark RV, Hermann DJ, Cunningham GR et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004 89 : 2179 84.
48. Roehrborn CG, Boyle P, Nickel JC et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002 60 : 434 41.
49. Debruyne F, Barkin J, van Erps P et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004 46 : 488 94.
50. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003 349 : 215 24.
51. Schulman C, Pommerville P, Höfner K et al. Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia. BJU Int 2006 97 : 73 9.
52. Andriole GL, Guess HA, Epstein JI et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Urology 1998 52 : 195 201.
53. Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate-specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol 2006 175 : 1657 62.
54. Thompson IM, Chi C, Ankerst DP et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006 98 : 1128 33.
55. Kirby RS, Roehrborn C, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the prospective European doxazosin and combination therapy (PREDICT) trial. Urology 2003 61 : 119 26.
56. Lepor H, Williford WO, Barry MJ et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs cooperative studies benign prostatic hyperplasia study group. N Engl J Med 1996 335 : 533 9.
57. Debruyne FM, Jardin A, Colloi D et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN study group. Eur Urol 1998 34 : 169 75.
58. Kaplan SA, McConnell JD, Roehrborn CG et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 2006 175 : 217 20.
59. Siami P, Roehrborn CG, Barkin J et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 2007 28 : 770 9.
60. ® and Tamsulosin (CombAT) study. Urology 2007 70 (Suppl. 3A 19.
61. Roehrborn C, Siami P, Barkin J et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008 179 : 616 21.
62. Baldwin KC, Ginsberg PC, Roehrborn CG et al. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001 58 : 203 9.
63. Barkin J, Guimarães M, Jacobi G et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 2003 44 : 461 6.
64. Marberger M. Drug insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia. Nat Clin Pract Urol 2006 3 : 495 503.